Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year?
Here is how Cencora (COR) and Intensity Therapeutics Inc. (INTS) have performed compared to their sector so far this year.
Cencora (COR) is a Top-Ranked Growth Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
3 Medical Services Industry Stocks to Buy as AI Fuels Growth
The Zacks Medical - Services industry is undergoing a transformation on massive artificial intelligence adoption. COR, DOCS and MD are set to gain the most.
Cencora (COR) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cencora, Inc. (COR) Hit a 52 Week High, Can the Run Continue?
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here is Why Growth Investors Should Buy Cencora (COR) Now
Cencora (COR) possesses solid growth attributes, which could help it handily outperform the market.
4 GARP Stocks That Investors Can Scoop Up for Maximum Returns
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. NVDA, COR, JBL and KLAC hold promise.
Here's Why You Should Add Cencora Stock to Your Portfolio Now
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Why Is Cencora (COR) Up 3.1% Since Last Earnings Report?
Cencora (COR) reported earnings 30 days ago. What's next for the stock?
3 Reasons Why Growth Investors Shouldn't Overlook Cencora (COR)
Cencora (COR) possesses solid growth attributes, which could help it handily outperform the market.
Cencora: Higher Potential Returns After Reduced Walgreens Stake
Cencora offers steady revenue growth from pharmaceutical distribution, benefiting from rising healthcare demand and an aging population. The company has a strong economic moat, low leverage, BBB+ credit rating, and an active share repurchase program, enhancing shareholder returns. Strategic acquisitions like Retina Consultants of America position Cencora for long-term success, with management guiding for 10% annual EPS growth.
Why Cencora (COR) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
